利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

207 条记录 (耗时 0.031 秒)

    THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS
    3.
    发明公开
    THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS 有权
    治疗组合进行痛苦的医疗条件

    公开(公告)号：EP2026788A1

    公开(公告)日：2009-02-25

    申请号：EP07725884.6

    申请日：2007-06-06

    申请人： SCHWARZ PHARMA AG

    发明人： BEYREUTHER, Bettina ,  STÖHR, Thomas

    IPC分类号： A61K31/165 ,  A61P21/00 ,  A61P19/00 ,  A61K31/00

    CPC分类号： Y02A50/401

    摘要： A therapeutic combination comprises a first agent comprising a compound as defined herein, illustratively lacosamide, or a pharmaceutically acceptable salt thereof, and a second agent effective in combination therewith to provide enhanced treatment of pain associated with or caused by a medical condition, by comparison with the first agent alone. The combination can be provided in a single dosage form or separate dosage forms and is illustratively useful for treatment of an arthritic condition and/or pain related thereto.

    PROCESS OF SULFONATING 4-AMINOBENZONITRILES
    6.
    发明公开
    PROCESS OF SULFONATING 4-AMINOBENZONITRILES 审中-公开
    磺化4-氨基苯甲腈的方法

    公开(公告)号：EP1910280A2

    公开(公告)日：2008-04-16

    申请号：EP06762729.9

    申请日：2006-07-20

    申请人： SCHWARZ PHARMA AG

    发明人： HAMANN, Jörg ,  KANZLER, Ralf ,  LI, Youxin

    IPC分类号： C07C303/36 ,  C07C311/08 ,  C07C335/12 ,  C07C331/06 ,  C07C331/24 ,  C07C303/40

    CPC分类号： C07C331/04 ,  C07C303/38 ,  C07C303/40 ,  C07C331/24 ,  C07C335/12 ,  C07C311/48 ,  C07C311/08

    摘要： A process of producing a compound of formula (3), wherein R1 is a C1-5 alkyl group, R2 is a halogen atom, a C1-5 alkyl group, a C2-5 alkenyl group, a C2-5 alkynyl group, a C1-5 alkyl group, a C1-5 alkoxy group, a nitro group, or a hydroxy group, wherein multiple R2 may be the same or may be different, and a is an integer of from 0 to 4, comprising reacting a compound of formula (2), wherein R2 and a are as defined above with a C1-5-alkanesulfonyl chloride or C1-5-alkanesulfonic acid anhydride followed by hydrolyzing an N,N-disulfonated derivative of compound (3) to the compound of formula (3).

    摘要翻译： 制备式（3）化合物的方法，其中R1为C1-5烷基，R2为卤原子，C1-5烷基，C2-5链烯基，C2-5炔基， C1-5烷基，C1-5烷氧基，硝基或羟基，其中多个R2可以相同或可以不同，并且a为0-4的整数，所述方法包括使化合物 其中R2和a如上所定义，其中R2和a与C1-5-链烷磺酰氯或C1-5-链烷磺酸酐反应，接着将化合物（3）的N，N-二磺化衍生物水解成式 3）。

    VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ROTIGOTIN-BASE
    9.
    发明授权
    VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ROTIGOTIN-BASE 有权
    DEVICE罗替戈汀基地透皮给药

    公开(公告)号：EP1490052B1

    公开(公告)日：2007-05-30

    申请号：EP03789421.9

    申请日：2003-12-24

    申请人： SCHWARZ PHARMA AG

    发明人： BREITENBACH, Armin

    IPC分类号： A61K31/381 ,  A61K9/70

    CPC分类号： A61K9/7069 ,  A61K31/381

    摘要： The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ñm, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.